Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417335 | 1.00 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL5613785 | 1.00 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL968867 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL968866 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL852586 | 0.83 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL13486701 | 0.76 | BACE1 (0.35) | — | |
| SCHEMBL4911804 | 0.73 | DUT (0.36) | — | |
| SCHEMBL4790841 | 0.73 | DUT (0.36) | — | |
| SCHEMBL15007568 | 0.72 | — | — | |
| SCHEMBL13734264 | 0.70 | NLRP3 (0.39) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387936-A1 | PROCESS OF ALPHA,BETA-DESATURATION OF COMPOUNDS CONTAINING A CARBONYL MOIETY | MINAKEM (FR) | 2021-12-16 | — | — | US | disclosed |
| EP-3922759-A1 | PROCESS OF ALPHA,BETA-DESATURATION OF COMPOUNDS CONTAINING A CARBONYL MOIETY | Minakem (FR) | 2021-12-15 | — | — | EP | disclosed |
| EP-2064170-B1 | CYCLOHEXANONE DERIVATIVES | BIOGEM S C AR L (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-8367735-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-8367735-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20090325901-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | ROSANTO PHARMACEUTICALS LTD. (GB) | 2009-12-31 | — | — | US | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060252839-A1 | Pharmaceutical compositions | BIOGEM S.C.A.R.L. (IT) | 2006-11-09 | — | — | US | disclosed |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20050124696-A1 | Pharmaceutical compositions | ROBERTS STANLEY M (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1487789-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Ltd. (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1456163-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003082813-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003051807-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | HSD17B7, CYP51A1, HSD11B1 | NFKB1 2582/4885NFKB2 3088/4885RELA 1994/4885 |
| US-20090325901-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | ARL1, RPS6KA2, ADSL | NFKB1 1698/4885NFKB2 752/4885RELA 2135/4885 |
| US-20210387936-A1 | PROCESS OF ALPHA,BETA-DESATURATION OF COMPOUNDS CONTAINING A CARBONYL MOIETY | SCD, COASY, ECH1 | NFKB1 690/4885NFKB2 796/4885RELA 884/4885 |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | HSD17B7, DHPS, DHCR7 | NFKB1 1923/4885NFKB2 2376/4885RELA 1195/4885 |
| US-20050124696-A1 | Pharmaceutical compositions | ADRM1, ARL1, UGT1A3 | NFKB1 3041/4885NFKB2 1205/4885RELA 4351/4885 |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | DHPS, HSD17B7, COASY | NFKB1 2079/4885NFKB2 2636/4885RELA 1818/4885 |
| US-20060252839-A1 | Pharmaceutical compositions | ADK, SYMPK, CYP2J2 | NFKB1 2339/4885NFKB2 946/4885RELA 3920/4885 |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | DHCR7, HSD17B7, HSD11B1 | NFKB1 2486/4885NFKB2 2532/4885RELA 1159/4885 |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | DHPS, CYP51A1, HSD17B7 | NFKB1 2781/4885NFKB2 3312/4885RELA 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.